Dr. Sylvia Adams is a renowned medical oncologist specializing in breast cancer at NYU Langone Health’s Perlmutter Cancer Center. She graduated from the University of Hamburg in Germany and completed her residency at Yale-New Haven Hospital. Board-certified in Medical Oncology, Dr. Adams has over 20 years of experience, focusing on immunotherapy in breast cancer. She is a recipient of the Breast Cancer Research Foundation Grant, the ASCO Career Development Award, and the AACR Women in Cancer Research Award. Dr. Adams is affiliated with the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer.
Education
- Medical School: University of Hamburg, Germany
- Residency: Yale-New Haven Hospital
- Board Certification: Medical Oncology
Awards
- Breast Cancer Research Foundation Grant Recipient
- ASCO Career Development Award
- AACR Women in Cancer Research Award
Professional Memberships and Affiliation
- American Society of Clinical Oncology (ASCO)
- Society for Immunotherapy of Cancer (SITC)
Clinical Experience
With two decades dedicated to oncology, Dr. Adams is a leader in integrating immunotherapy into breast cancer treatment. She has been instrumental in conducting groundbreaking clinical trials that have introduced immune checkpoint inhibitors as viable options for patients with triple-negative breast cancer. Her research explores the tumor microenvironment and the role of immunomodulation, aiming to enhance the body’s natural defenses against cancer. Dr. Adams combines her research expertise with compassionate patient care, offering cutting-edge treatments while supporting patients through their journey. She actively collaborates with multidisciplinary teams to provide holistic care and is committed to educating patients about emerging therapies. Her efforts have significantly expanded treatment horizons, offering new hope to patients with challenging forms of breast cancer.
Research and Publications
- Adams S, Diamond JR, Hamilton E, et al. “Atezolizumab Plus Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.” JAMA Oncology.
- Adams S, Schmid P, Rugo HS, et al. “Pembrolizumab Monotherapy for Previously Untreated, PD-L1–Positive, Metastatic Triple-Negative Breast Cancer.” Annals of Oncology
- Adams S. “Immune Checkpoint Blockade in Triple-Negative Breast Cancer.” Cancer Journal.
Dr. Sylvia Adams
Medical Oncologist
Cancer Treated:
- 160 East 34th Street, New York, NY 10016
- (212) 731-6549
Dr. Sylvia Adams is a renowned medical oncologist specializing in breast cancer at NYU Langone Health’s Perlmutter Cancer Center. She graduated from the University of Hamburg in Germany and completed her residency at Yale-New Haven Hospital. Board-certified in Medical Oncology, Dr. Adams has over 20 years of experience, focusing on immunotherapy in breast cancer. She is a recipient of the Breast Cancer Research Foundation Grant, the ASCO Career Development Award, and the AACR Women in Cancer Research Award. Dr. Adams is affiliated with the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer.